ARA290


THE INFLAMMATION-MODULATING, NERVE-SUPPORT PEPTIDE

ARA-290 (Cibinetide) is a synthetic peptide designed to activate the innate repair receptor, helping reduce inflammation, support neural repair, and improve microvascular function without stimulating red blood cell production. Unlike erythropoietin (EPO), which activates multiple pathways, ARA-290 selectively targets the tissue-protective signaling arm, making it safer and more precise. Early human trials show promising results for neuropathic pain, sarcoidosis-related small fiber neuropathy, and inflammatory tissue injury. At our clinic, ARA-290 is offered as an investigational therapy within comprehensive recovery and inflammation-support protocols.

Get Approved

IMPROVING YOUR INNATE HEALING

Here’s how ARA290 helps healing and neurological function.

  1. Reduces Neuropathic Pain: Human clinical trials show improved symptoms in small fiber neuropathy, including pain reduction and better autonomic function.

  2. Modulates Inflammation: Selectively activates the innate repair receptor to reduce inflammatory cytokines without suppressing immune function.

  3. Supports Nerve Repair & Regeneration: Demonstrated ability to improve corneal nerve fiber density and skin nerve fiber regeneration in clinical studies.

  4. Improves Microvascular Function: Enhances tissue perfusion and endothelial health, supporting recovery in inflamed or ischemic tissues.

  5. Protects Tissues Under Stress: Offers cytoprotective effects during injury, oxidative stress, or metabolic strain.

RELEVANT STUDIES

Read below for studies endorsing the use of ARA290.

  1. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy — Double-Blind Pilot Study (2012)
    This randomized, placebo-controlled trial found that ARA-290 reduced neuropathic symptoms and improved measures of small-fiber neuropathy versus placebo, with a favorable safety profile.

  2. ARA-290 (Cibinetide) Improves Corneal Nerve Fiber Density in Neuropathy — IOVS (2017)
    In this clinical study, ARA-290 significantly increased corneal small nerve fiber density (a marker for nerve regeneration) in patients with small-fiber neuropathy, supporting a regenerative effect.

  3. Preclinical Neuropathic Pain Models — ARA-290 Reduces Allodynia and Neuroinflammation (2014)
    In animal models of nerve injury, ARA-290 dose-dependently reduced mechanical and cold allodynia (pain sensitivity), and suppressed spinal microglia activation — offering mechanistic evidence for its tissue-protective and anti-inflammatory effects.

  4. Targeting the Innate Repair Receptor to Treat Neuropathy — Review / Clinical Data Synthesis (2016)
    This paper reviews both animal and human data, concluding that ARA-290 effectively shifts a pro-inflammatory, tissue-damaging environment into one favoring healing and repair — with observed improvements in neuropathy symptoms and nerve fiber metrics, and without major adverse effects.

    Note: ARA-290 has some human clinical support, especially for small-fiber neuropathy (SFN) associated with conditions like sarcoidosis (and also studied in diabetic neuropathy).

    The positive findings include symptomatic improvement (pain, autonomic symptoms) and structural or regenerative markers (nerve fiber density in cornea or skin).

    Most other proposed uses — e.g., broad “regenerative medicine,” systemic inflammation, or performance enhancement — remain theoretical or preclinical. There is no large-scale FDA-approved indication outside of research or compassionate-use contexts.

    Because ARA-290 is still investigational for many uses, any clinical offering must be framed carefully: “off-label,” “pilot/early evidence,” “not a guaranteed cure.”

Get Approved
peptide, therapy, Houston, muscle, regenerate, strength, recovery

FAQs

  • ARA-290 is primarily studied for neuropathic pain, small fiber neuropathy, inflammatory conditions, and tissue repair through activation of the innate repair receptor. It is investigational and not FDA-approved for these indications.

  • It targets the innate repair receptor (IRR) — a pathway responsible for tissue protection, anti-inflammatory signaling, and nerve repair. This allows ARA-290 to promote healing without the red blood cell–stimulating effects of erythropoietin.

  • Clinical trials report a strong safety profile with minimal side effects, especially compared to EPO-derived molecules. Long-term safety for wellness or off-label use is still being studied.

  • ARA-290 has shown promise in:

    • small fiber neuropathy

    • neuropathic pain

    • sarcoidosis-related nerve damage

    • microvascular dysfunction

    • chronic inflammatory states

  • It is typically administered via subcutaneous injections, with dosing protocols determined based on goals, symptoms, and clinical history.

  • In clinical trials, improvements in neuropathic symptoms often emerged within 2–4 weeks. Tissue repair and microvascular improvements may take longer and depend on consistency.

  • Yes. It may complement peptides, regenerative therapies, mitochondrial support strategies, and functional medicine protocols. All combinations should be medically supervised.

  • No. It is an investigational peptide used off-label based on emerging evidence and clinical judgment.

Huemn offers ARA290 peptide therapy in Houston, serving clients from The Heights, Vintage Park, Cypress, and surrounding areas seeking advanced immune and longevity support.

Disclaimer: The statements and content presented on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). We do not diagnose, treat, or claim to treat any health conditions. All services provided by Huemn are intended solely to promote overall wellness, and information on this site is published for educational purposes. Always consult with a healthcare professional before making any decisions related to your health.